Vol.1 No.3 2009

9/69

Research paper : Development of regenerative medical technology working toward practical application (H. Ohgushi)−160 Synthesiology - English edition Vol.1 No.3 (2009) Discussion with reviewers1 Need for technology utilizing MSCQuestion (Hiroshi Kuriyama)I think it is necessary to mention briefly why it is necessary to use patient-derived MSC in the Introduction. I think it is also necessary to describe the danger of iPS cell (as response to common question why iPS, which is frequently highlighted in the media, cannot be used).Answer (Hajime Ohgushi)In the Introduction, I added the description that iPS cell may cause tumor called teratoma when it is transplanted.2 Importance of bone and cartilage treatmentQuestion (Hiroshi Kuriyama)Perhaps you should explain how many cases require bone and cartilage regeneration treatment where this technology can be applied, as well as projection of demand in Japan and other countries in Section 4. Also, I think if you include the numbers of other cases and patients who may benefit from this medical technology, the efficacy of this technological development may become clearer (how about showing the patient figures in table?). Although the data may be available in Reference #6, maybe you should indicate the actual case figures and treatment results for bone and cartilage treatment.Answer (Hajime Ohgushi)I added the number of patients with arthropathy and the projected number of patients to whom regenerative medicine may be indicated. I also added the figures for patients with heart disease. The actual number of regenerative treatment for arthropathy that we conducted is 50 or so cases, so I described it as over 50 patients. Detailed description of the treatment result increases the number of words and departs from the main subject, so I simply stated that we have not observed “loosening” at implant site which is adverse event for artificial joint and that good result is maintained.(6)−

※このページを正しく表示するにはFlashPlayer9以上が必要です